A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy
View/ Open
Access
info:eu-repo/semantics/openAccessAttribution-NonCommercial 4.0 Internationalhttps://creativecommons.org/licenses/by-nc/4.0/Date
2024Author
Kılıçkap, SaadettinÖztürk, Akın
Karadurmuş, Nuri
Korkmaz, Taner
Yumuk, Perran Fulden
Çiçin, İrfan
Paydaş, Semra
Çılbır, Ebru
Şakalar, Teoman
Uysal, Mükremin
Yeşil Çınkır, Havva
Üskent, Necdet
Demir, Necla
Sakin, Abdullah
Dursun, Oldaç Uras
Aver, Birkan
Turhal, Nazım Serdar
Keskin, Serkan
Tural, Deniz
Eralp, Yeşim
Buğdaycı Başal, Fatma
Yaşar, Hatime Arzu
Şendur, Mehmet Ali Nahit
Demirci, Umut
Çubukçu, Erdem
Karaağaç, Mustafa
Çakar, Burcu
Tatlı, Ali Murat
Yetişyiğit, Tarkan
Urvay, Semiha
Gürsoy, Pınar
Oyan, Başak
Turna, Zeynep Hande
Işıkdoğan, Abdurrahman
Ölmez, Ömer Fatih
Yazıcı, Ozan
Çabuk, Devrim
Şeker, Mehmet Metin
Ünal, Olçun Ümit
Meydan, Nezih
Okutur, Sadi Kerem
Tunalı, Didem
Erman, Mustafa
Metadata
Show full item recordCitation
Kılıçkap, S., Öztürk, A., Karadurmuş, N., Korkmaz, T., Yumuk, P. F., Çiçin, İ. ... Erman, M. (2024). A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy. Medicine (United States), 103(21), E37972. http://dx.doi.org/10.1097/MD.0000000000037972Abstract
To evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, retrospective archive screening study evaluated demographic, clinical, and radiological imaging features, and treatment approaches in patients treated between 2013-2017. Totally 367 patients (54.8% males, median age at diagnosis 54 years) were included. Of them, 45.4% were smokers, and 8.7% had a family history of lung cancer. On radiological findings, 55.9% of the tumors were located peripherally, 7.7% of the patients had cavitary lesions, and 42.9% presented with pleural effusion. Pleural effusion was higher in nonsmokers than in smokers (37.3% vs. 25.3%, P = .018). About 47.4% of cases developed distant metastases during treatment, most frequently to the brain (26.2%). Chemotherapy was the first line treatment in 55.0%. Objective response rate was 61.9% (complete response: 7.6%; partial response: 54.2%). The highest complete and partial response rates were observed in patients who received crizotinib as the 2nd line treatment. The median progression-free survival was 14 months (standard error: 1.4, 95% confidence interval: 11.2-16.8 months). Crizotinib treatment lines yielded similar progression-free survival (P = .078). The most frequent treatment-related adverse event was fatigue (14.7%). Adrenal gland metastasis was significantly higher in males and smokers, and pleural involvement and effusion were significantly higher in nonsmokers - a novel finding that has not been reported previously. The radiological and histological characteristics were consistent with the literature data, but several differences in clinical characteristics might be related to population characteristics.
WoS Q Kategorisi
Q2xmlui.dri2xhtml.METS-1.0.item-scopusquality
Q3Source
Medicine (United States)Volume
103Issue
21Collections
- Makale Koleksiyonu [3801]
- PubMed İndeksli Yayınlar Koleksiyonu [4264]
- Scopus İndeksli Yayınlar Koleksiyonu [6620]
- WoS İndeksli Yayınlar Koleksiyonu [6696]